ES2259602T3 - Secuencias antitumor antisentido dirigidas contra los componentes r1 y r2 del ribonucleotido reductasa. - Google Patents

Secuencias antitumor antisentido dirigidas contra los componentes r1 y r2 del ribonucleotido reductasa.

Info

Publication number
ES2259602T3
ES2259602T3 ES00903456T ES00903456T ES2259602T3 ES 2259602 T3 ES2259602 T3 ES 2259602T3 ES 00903456 T ES00903456 T ES 00903456T ES 00903456 T ES00903456 T ES 00903456T ES 2259602 T3 ES2259602 T3 ES 2259602T3
Authority
ES
Spain
Prior art keywords
sequence
seq
prevent
antisense oligonucleotide
reduced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00903456T
Other languages
English (en)
Inventor
Jim A Wright
Aiping H Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genesense Technologies Inc
Original Assignee
Genesense Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genesense Technologies Inc filed Critical Genesense Technologies Inc
Application granted granted Critical
Publication of ES2259602T3 publication Critical patent/ES2259602T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it

Abstract

La presente invención proporciona un oligonucleótido de menos de 50 nucleótidos que comprenden la secuencia de AS-I-618-20 [SEQ ID NO:176]. Esta secuencia pude además comprender una formación dímera reducida e interacciones auto-complementarias reducidas. También se proporciona una composición farmacéutica para impedir el crecimiento de la célula tumorosa en un mamífero que comprende una cantidad efectiva de oligonucleótido antisentido de menos de 50 nucleótidos que comprenden la secuencia de AS-I-618-20 [SEQ ID NO:176]. En uno de los aspectos de su método, esta invención proporciona un método para impedir la capacidad de generar tumores de células neoplásticas en un mamífero, cuyo método comprende el contacto de la célula neoplástica con una cantidad efectiva de oligonucleótido antisentido que comprende la secuencia de AS-I-618-20 [SEQ ID NO: 176]. Otro aspecto es un método para impedir la capacidad de generar tumores de las células neoplásticas resistentes a los medicamentos quimioterapéuticos en un mamífero, cuyo método comprende la identificación de pacientes que tienen tumores resistentes a la droga quimioterapéutica; y poniendo en contacto el tumor con la droga quimioterapéutica a la que el tumor es resistente y un oligonucleótido antisentido que comprenda la secuencia de AS-I-618-20 [SEQ ID NO:176] de forma que la cantidad de droga quimioterapéutica y de oligonucleótido antisentido es suficiente para impedir el crecimiento de la célula tumorosa.
ES00903456T 1999-02-11 2000-02-09 Secuencias antitumor antisentido dirigidas contra los componentes r1 y r2 del ribonucleotido reductasa. Expired - Lifetime ES2259602T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/249,730 US6121000A (en) 1999-02-11 1999-02-11 Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase

Publications (1)

Publication Number Publication Date
ES2259602T3 true ES2259602T3 (es) 2006-10-16

Family

ID=22944744

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00903456T Expired - Lifetime ES2259602T3 (es) 1999-02-11 2000-02-09 Secuencias antitumor antisentido dirigidas contra los componentes r1 y r2 del ribonucleotido reductasa.

Country Status (17)

Country Link
US (1) US6121000A (es)
EP (1) EP1153128B8 (es)
JP (1) JP4424857B2 (es)
KR (1) KR20020013501A (es)
CN (1) CN1345373A (es)
AR (1) AR022583A1 (es)
AT (1) ATE309346T1 (es)
AU (1) AU780455B2 (es)
BR (1) BR0008788A (es)
CA (1) CA2366487A1 (es)
DE (1) DE60023845T2 (es)
ES (1) ES2259602T3 (es)
IL (1) IL144727A0 (es)
MX (1) MXPA01008137A (es)
NZ (1) NZ514090A (es)
RU (1) RU2001124840A (es)
WO (1) WO2000047733A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593305B1 (en) * 1996-08-02 2003-07-15 Genesense Technologies Inc. Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
MXPA04010282A (es) * 2002-04-18 2005-08-18 Acuity Pharmaceuticals Inc Medios y metodos para la inhibicion especifica de genes en celulas y tejido de cns y/u ojo.
US7148342B2 (en) * 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
JP2006518344A (ja) * 2003-02-10 2006-08-10 ジェネセンス テクノロジーズ インク リボヌクレオチド還元酵素ｒ２を指向するアンチセンスオリゴヌクレオチドおよび癌の治療におけるこれらの使用
EP1615943A4 (en) * 2003-04-18 2006-08-16 Univ Pennsylvania COMPOSITIONS AND METHODS FOR INHIBITING ARNIC OF ANGIOPOIETIN 1 AND 2 AND THEIR TIE2 RECEPTOR
CN1302936C (zh) * 2003-05-02 2007-03-07 精工爱普生株式会社 打印机
EP1636363A1 (en) * 2003-05-21 2006-03-22 GeneSense Technologies Inc. Antisense oligonucleotides directed to ribonucleotide reductase r1 and uses thereof in the treatment of cancer
WO2004106518A1 (en) * 2003-05-31 2004-12-09 Genesense Technologies Inc. Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in the treatment of cancer
CA2533701A1 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
WO2005065719A1 (en) * 2004-01-12 2005-07-21 Genesense Technologies Inc. Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in combination therapies for the treatment of cancer
CA2564868C (en) * 2004-04-28 2013-11-26 Molecules For Health, Inc. Methods for treating or preventing restenosis and other vascular proliferative disorders
WO2006017932A1 (en) * 2004-08-18 2006-02-23 Genesense Technologies Inc. Small interfering rna molecules against ribonucleotide reductase and uses thereof
US20090130212A1 (en) * 2006-05-15 2009-05-21 Physical Pharmaceutica, Llc Composition and improved method for preparation of small particles
WO2007146953A2 (en) * 2006-06-12 2007-12-21 Exegenics, Inc., D/B/A Opko Health, Inc. Compositions and methods for sirna inhibition of angiogenesis
US7872118B2 (en) * 2006-09-08 2011-01-18 Opko Ophthalmics, Llc siRNA and methods of manufacture
US20080305157A1 (en) * 2007-06-08 2008-12-11 University Of Maryland Office Of Technology Commercialization Encapsulation and separation of charged organic solutes inside catanionic vesicles
EP2030615A3 (en) * 2007-08-13 2009-12-02 ELFORD, Howard L. Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases
US20100204305A1 (en) * 2007-12-11 2010-08-12 Lorus Therapeutics Inc. Small interfering rna molecules against ribonucleotide reductase and uses thereof
CA2745832A1 (en) 2008-12-04 2010-06-10 Opko Ophthalmics, Llc Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms
DE102019000490A1 (de) * 2019-01-23 2020-07-23 HAEMES Verwaltungsgesellschaft mbH Verwendung von Oligonukleotiden für die Behandlung von Tumoren

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034506A (en) * 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5225347A (en) * 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Therapeutic ribozyme compositions and expression vectors
US5719262A (en) * 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5766855A (en) * 1991-05-24 1998-06-16 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity and sequence specificity
US5681747A (en) * 1992-03-16 1997-10-28 Isis Pharmaceuticals, Inc. Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof
EP0690869A1 (en) * 1993-03-23 1996-01-10 The Board Of Trustees Of The Leland Stanford Junior University Cellular regulation with riboregulators
WO1998005769A2 (en) * 1996-08-02 1998-02-12 Genesense Technologies, Inc. Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase

Also Published As

Publication number Publication date
WO2000047733A1 (en) 2000-08-17
EP1153128B1 (en) 2005-11-09
RU2001124840A (ru) 2004-03-27
DE60023845D1 (de) 2005-12-15
EP1153128A1 (en) 2001-11-14
KR20020013501A (ko) 2002-02-20
ATE309346T1 (de) 2005-11-15
AR022583A1 (es) 2002-09-04
AU780455B2 (en) 2005-03-24
DE60023845T2 (de) 2006-08-10
JP4424857B2 (ja) 2010-03-03
CA2366487A1 (en) 2000-08-17
BR0008788A (pt) 2001-11-06
AU2529200A (en) 2000-08-29
EP1153128B8 (en) 2006-01-18
WO2000047733A9 (en) 2001-03-15
JP2003500006A (ja) 2003-01-07
US6121000A (en) 2000-09-19
CN1345373A (zh) 2002-04-17
NZ514090A (en) 2005-01-28
IL144727A0 (en) 2002-06-30
MXPA01008137A (es) 2004-08-12

Similar Documents

Publication Publication Date Title
ES2259602T3 (es) Secuencias antitumor antisentido dirigidas contra los componentes r1 y r2 del ribonucleotido reductasa.
ES2749374T3 (es) Compuestos inhibitorios dirigidos a conexina 43 y sus métodos de uso en el tratamiento del trauma ocular de la córnea
US9764035B2 (en) Methods and compositions for treating prostate cancer
US20090131360A1 (en) Tripartite RNAi constructs
US20110111056A1 (en) Peptide dicer substrate agents and methods for their specific inhibition of gene expression
BR0112361A (pt) Métodos para tratamento de condições oculares mediadas por inflamação
CO6241169A2 (es) Metodos para el tratamiento de hipercolesterolemia
PA8568201A1 (es) Terapias de combinacion para tratar celulas deficientes en metiltioadenosina-fosforilasa
SI2999785T1 (en) SERPINA1 IRNA assemblies and procedures for their use
US9080173B2 (en) Methods and compositions for RNAi-based cancer treatment
BR0109266A (pt) Composto, composição farmacêutica, método de tratamento de um mamìfero afetado com um câncer, método de liberação de um composto nas células de um mamìfero afetado com um câncer e uso do composto
AR054526A1 (es) Metodo para tartar pacientes con una vacuna de glicoproteina mucinosa (muc-1)
US20150238517A1 (en) Methods and compositions for treating cancer
EP2216029A3 (en) Oligonucleotides for treatment of prostate and other cancers
FR2790757B1 (fr) Oligonucleotides contenant une sequence antisens stabilises par une structure secondaire et compositions pharmaceutiques les contenant.
RU2651493C2 (ru) NOTCH 1-СПЕЦИФИЧЕСКИЕ МОЛЕКУЛЫ миРНК
CA2466732A1 (en) Telomerase interference
BRPI0713111A2 (pt) oligonucleotìdeos que afetam a expressão das fosfodiesterases
WO2005028617A3 (en) Antisense inhibition of laminin-8 expression to inhibit human gliomas
WO2007121054A3 (en) Nucleic acids for apoptosis of cancer cells
US7393950B2 (en) Antisense oligonucleotides targeted to human CDC45
ATE537838T1 (de) Kombinationstherapie mit kloretazin(tm)
US20080300212A1 (en) Treatment and prevention of hyperproliferative conditions in humans and antisense oligonucleotide inhibition of human replication-initiation proteins
WO2023197009A2 (en) Compositions and methods for treatment of cancers using modified sirna-gem agents
ITMI980356A1 (it) Composizioni orali a basso dosaggio di proteine citotossiche